AtriCure, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael H. Carrel
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 7555 Innovation Way Mason OH United States of America 45040
- IPO Date
- Aug 5, 2005
- CIK
- 0001323885
- Website
- atricure.com
- Similar Companies
- Business
- AtriCure, Inc. develops, manufactures, and sells advanced medical devices primarily for the surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its core product portfolio includes surgical ablation systems such as the Isolator® Synergy™ Access® Clamp, Isolator® Synergy™ Clamps, and the Isolator® Transpolar Pen; the AtriClip® devices for LAA exclusion including models like AtriClip PRO®, AtriClip FLEX™, and their Mini variants; cryoSPHERE® devices and related probes for cryo nerve block therapy targeting pain management; and minimally invasive surgical instruments including the EPi-Ease™ Epicardial Access Device and atrial lift systems. The company also offers hybrid total thoracoscopic therapy for long-standing persistent Afib. Founded in 2000 and headquartered in Mason, Ohio, AtriCure operates globally, targeting cardiac surgeons, electrophysiologists, and hospitals involved in cardiac surgery. Recent major changes include the successful launch of new products like the AtriClip Flex Mini and cryoSPHERE MAX probes, which have driven accelerated growth in appendage and pain management segments. The company achieved significant revenue growth for 2025, projecting revenues between $532 million and $534 million, which represents double-digit percentage increases year over year. AtriCure also advanced development in pulse field ablation (PFA) technology for cardiac surgery and expanded its global manufacturing and R&D facilities in Mason, Ohio. Additionally, the company completed strategic acquisitions earlier, such as that of Estech, enhancing its surgical ablation portfolio with radio-frequency technologies. These developments reinforce AtriCure’s leadership position in surgical Afib treatments, LAA management, and postoperative pain therapies across multiple international markets.
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure Reports First Quarter 2026 Financial Results
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts
AtriCure to Announce First Quarter 2026 Financial Results
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Analysts
Citigroup Inc. Purchases 36,839 Shares of AtriCure, Inc. $ATRC
AtriCure to Participate in the Citizens Life Sciences Conference
AtriCure Q4 Earnings Call Highlights
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results